Literature DB >> 25606168

High-risk behaviours and concomitant medical illnesses among patients at methadone maintenance therapy clinic, hospital tengku ampuan afzan, malaysia.

M Ramli, Mz Nora, Aab Zafri, Mr Junid, Ak Umeed, Mi Hajee.   

Abstract

BACKGROUND: High prevalence of high-risk behaviours and concurrent medical illnesses among opioid drug users would influence the outcome of Methadone Maintenance Programme. It would also require a special medical attention to contain these issues.
OBJECTIVES: This study explored patients' characteristics and their high-risk behaviours in order to understand more about opioid dependent users in Malaysia.
METHODS: A total of 172 patient case notes at Methadone Clinic Hospital Tengku Ampuan Afzan (HTAA) were retrieved for relevant data.
RESULTS: Many of the patients were engaged in high-risk behaviours such as needle sharing, unsafe sex and criminal activities. A large number of the subjects had contracted blood-borne diseases such as HIV and hepatitis infections.
CONCLUSIONS: Education on the issue of medical and psychosocial complications related to high risk behaviours is essential. Medical professionals dealing with this group have to pay attention and update their knowledge on the medical issue.

Entities:  

Keywords:  Methadone therapy; high-risk behaviours; opioid dependence

Year:  2009        PMID: 25606168      PMCID: PMC4267043     

Source DB:  PubMed          Journal:  Malays Fam Physician        ISSN: 1985-2274


  6 in total

1.  Risk factors associated with noncompliance with methadone substitution therapy (MST) and relapse among chronic opiate users in an Outer London community.

Authors:  H C Mutasa
Journal:  J Adv Nurs       Date:  2001-07       Impact factor: 3.187

2.  A six-year evaluation of methadone prescribing practices at a substance misuse treatment centre in the UK.

Authors:  G L Dickinson; A Rostami-Hodjegan; O Lagundoye; N Seivewright; P Pratt; M S Lennard
Journal:  J Clin Pharm Ther       Date:  2006-10       Impact factor: 2.512

3.  Malaysia and harm reduction: the challenges and responses.

Authors:  Gary Reid; Adeeba Kamarulzaman; Sangeeta Kaur Sran
Journal:  Int J Drug Policy       Date:  2007-01-29

4.  Methadone maintenance 4 decades later: thousands of lives saved but still controversial.

Authors:  Herbert D Kleber
Journal:  JAMA       Date:  2008-11-19       Impact factor: 56.272

5.  HIV infection among injecting drug users in north-east Malaysia, 1992.

Authors:  S Singh; N Crofts
Journal:  AIDS Care       Date:  1993

Review 6.  The alkaloids of Mitragyna with special reference to those of Mitragyna speciosa, Korth.

Authors:  E J Shellard
Journal:  Bull Narc       Date:  1974 Apr-Jun
  6 in total
  5 in total

1.  Can Primary Care Clinic Run MMT Service Well?

Authors:  A Norsiah; S Dharmananda; Md Mohammad Nazri; Mm Marzafuan; Bwh Lee; My Khalijah
Journal:  Malays Fam Physician       Date:  2010-04-30

2.  The Effectiveness of Methadone Maintenance Therapy Among Opiate - Dependants Registered with Hospital Raja Perempuan Zainab II Kota Bharu, Kelantan.

Authors:  Jeganathan Premila Devi; Ab Rahman Azriani; Wan Mohd Zahiruddin; Mohd Noor Mohd Ariff; Abdullah Noor Hashimah
Journal:  Malays J Med Sci       Date:  2012-10

3.  The Prevalence and Psychosocial Correlates of Ketum (Mitragyna speciosa) Use among Individuals on Methadone Maintenance Therapy Programme in Hospital Taiping, Malaysia.

Authors:  Ling Ling Choo; Muhammad Muhsin Ahmad Zahari; Seng Kit Choy; Naemah Abdul Rahim; Rusdi Abd Rashid
Journal:  Healthcare (Basel)       Date:  2022-04-17

4.  Improvement of quality of life following 6 months of methadone maintenance therapy in Malaysia.

Authors:  Nizam Baharom; Mohd Rohaizat Hassan; Norsiah Ali; Shamsul Azhar Shah
Journal:  Subst Abuse Treat Prev Policy       Date:  2012-08-01

5.  Sexual Dysfunction in Heroin Dependents: A Comparison between Methadone and Buprenorphine Maintenance Treatment.

Authors:  Anne Yee; Mahmoud Danaee; Huai Seng Loh; Ahmad Hatim Sulaiman; Chong Guan Ng
Journal:  PLoS One       Date:  2016-01-28       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.